JERUSALEM, October 3, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)
(http://www.oramed.com), a developer of oral drug delivery systems,
announced today that it has received two additional patent
approvals for its platform Protein Oral Delivery (POD™) technology
in Japan and Canada. Both granted patents are titled
"Methods and Compositions for Oral Administrations of
Proteins."
About POD™ Technology
Oramed's proprietary Protein Oral Delivery (POD™) technology is
based on over 30 years of research by top scientists at
Jerusalem's Hadassah Medical
Center. Addressing the obstacles to the oral administration of
small protein (peptide) molecules, POD™ technology both protects
and enhances protein delivery and absorption via the digestive
system and into the bloodstream. In this way Oramed's POD™
technology can be used to develop oral alternatives for a number of
today's injectable therapies.
For more information on Oramed's POD™ technology, please refer
to the Company website: http://www.oramed.com
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs and vaccines currently delivered
via injection. Established in 2006 and based on Oramed's platform
POD™ technology, Oramed is seeking to revolutionize the treatment
of diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801) currently initiating Phase 2
clinical trials on patients with type 2 diabetes (T2DM) under an
Investigational New Drug application with the U.S. Food and Drug
Administration, and with its oral exenatide capsule (ORMD-0901; a
GLP-1 analog), with trials on healthy volunteers (Phase 1b) and
T2DM patients (Phase 2a) underway. Oramed is also moving forward
with clinical trials of ORMD-0801 for the treatment of type 1
diabetes. The company's corporate and R&D headquarters are
based in Jerusalem.
For more information, the content of which is not part of this
press release, please visit http://www.oramed.com.
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss our clinical trials or
revolutionizing the treatment of diabetes with our products. These
forward-looking statements and their implications are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
Mobile: +972-54-792-4438
Email: aviva@oramed.com
SOURCE Oramed Pharmaceuticals Inc.